Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minutes Matter: Why The US FDA Refuses To Record Formal Meetings

Executive Summary

Given confusion sometimes emerges about the content of formal meeting minutes, recording the meetings would seem like an easy solution, but also could muddy the administrative record.

You may also be interested in...



Gene Therapy: Nonclinical Questions Do Not Seem Ideal For The US FDA’s New Type D Meeting

Nonclinical testing questions should be answered in a pre-IND meeting, rather than the new Type D session. A US FDA Center for Biologics Evaluation and Research official also indicated support for alternatives to animal testing when possible.

Pilot Phase Of Operation Warp Speed For Rare Diseases Beginning Soon

US FDA’s biologics center intends to ask for volunteers to help demonstrate the concept, modeled on the COVID vaccine effort, which includes speedier communication with sponsors to expedite development of products for rare diseases.

US FDA’s Oncology Divisions Have Been Providing Live Meeting Minutes For Years. Will Others Follow?

Oncology division officials summarize the agreements and discussions reached during formal meetings so there are no misunderstandings later. Sponsors want the practice used more widely by the FDA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel